STOCK TITAN

HSDT: Investor Group Buys 17% for $47M; CHEE Named Executive Chairman

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Fusion Summer Limited and CHEE Choon Wee disclosed a joint Schedule 13D reporting the acquisition of 6,830,402 shares of Helius Medical Technologies Class A common stock, representing 17.0% of the outstanding shares based on 40,295,612 shares. Fusion Summer paid approximately $47.0 million in a private placement (PIPE) that closed on September 18, 2025. Mr. CHEE, the ultimate controller of Fusion Summer, was appointed Executive Chairman effective at closing. The reporting persons hold shared voting and dispositive power over the shares and state the securities were acquired for investment purposes.

Positive

  • Acquisition of 6,830,402 shares representing 17.0% of Class A, a material minority stake
  • Approximately $47.0 million injected into the company via the PIPE transaction, providing liquidity
  • Appointment of CHEE Choon Wee as Executive Chairman aligns the investor with board-level influence

Negative

  • Shared voting and dispositive power only; reporting persons do not claim sole control over the shares
  • No specific plans disclosed to propose changes to the company’s business, operations, governance, or capitalization

Insights

TL;DR: A single investor group acquired a material 17% stake and provided $47M in PIPE financing, increasing investor influence.

The acquisition of 6.83 million shares for approximately $47.0 million creates a meaningful minority position equal to 17% of the Class A float, which is likely to affect liquidity and shareholder dynamics. The concurrent appointment of Mr. CHEE as Executive Chairman strengthens governance influence tied to the investment. The filing states the shares were bought for investment purposes and leaves open potential future actions, which could include further purchases or disposals depending on market and company developments.

TL;DR: The investor gains substantial board influence but reports only shared voting power and no immediate change proposals.

The Schedule 13D documents both ownership and the governance link via Mr. CHEE's Executive Chairman role. While a 17% stake plus chairmanship signals increased control potential, the filing discloses shared rather than sole voting or dispositive power and expressly notes no present plans to propose specified governance changes. This leaves the degree and direction of activist engagement uncertain.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Rows 8, 10 and 11: Consists of 6,830,402 shares of Class A Common Stock (the "Common Stock") held directly by Fusion Summer Limited and acquired pursuant to the Securities Purchase Agreement as further described in Item 3 and Item 6. Note to Row 13: The percentage of beneficial ownership is calculated based on 40,295,612 shares outstanding as of September 24, 2025 (which number was provided by the Issuer to the Reporting Persons).


SCHEDULE 13D




Comment for Type of Reporting Person:
Note to Rows 8, 10 and 11: Consists of (6,830,402 shares of Class A Common Stock (the "Common Stock") beneficially owned by Mr. CHEE, who is the ultimate controlling person of Fusion Summer Limited. Note to Row 13: The percentage of beneficial ownership is calculated based on 40,295,612 shares outstanding as of September 24, 2025 (which number was provided by the Issuer to the Reporting Persons).


SCHEDULE 13D


Fusion Summer Limited
Signature:/s/ CHEE Choon Wee
Name/Title:CHEE Choon Wee, Director
Date:10/02/2025
CHEE Choon Wee
Signature:/s/ CHEE Choon Wee
Name/Title:CHEE Choon Wee, Individually
Date:10/02/2025

FAQ

How many HSDT shares did Fusion Summer Limited purchase and what percent of the company does that represent?

Fusion Summer acquired 6,830,402 shares, representing 17.0% of Class A common stock based on 40,295,612 shares outstanding.

How much did Fusion Summer pay for its HSDT shares in the PIPE transaction?

The aggregate purchase price was approximately $47.0 million for the 6,830,402 shares.

When did the PIPE transaction close and when was the Schedule 13D event date?

The transaction closed on September 18, 2025, and the Schedule 13D reports the relevant event date as September 18, 2025.

Does CHEE Choon Wee control the shares directly?

Mr. CHEE is the ultimate controlling person of Fusion Summer and is deemed to share voting and dispositive power over the 6,830,402 shares; he does not report sole voting or dispositive power.

Did the reporting persons state any current plans to change Helius Medical Technologies’ operations or governance?

They stated the shares were acquired for investment purposes and have no present plans to effect the specific actions listed in Item 4, while reserving the right to review and potentially act in the future.
Solana Company

NASDAQ:HSDT

HSDT Rankings

HSDT Latest News

HSDT Latest SEC Filings

HSDT Stock Data

142.49M
30.57M
0.66%
1.46%
1.42%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEWTOWN